[go: up one dir, main page]

DK3353212T3 - Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf - Google Patents

Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf Download PDF

Info

Publication number
DK3353212T3
DK3353212T3 DK16781236.1T DK16781236T DK3353212T3 DK 3353212 T3 DK3353212 T3 DK 3353212T3 DK 16781236 T DK16781236 T DK 16781236T DK 3353212 T3 DK3353212 T3 DK 3353212T3
Authority
DK
Denmark
Prior art keywords
antibodies
bispecific anti
optimized bispecific
optimized
bispecific
Prior art date
Application number
DK16781236.1T
Other languages
English (en)
Inventor
Eric Smith
Lauric Haber
Robert Babb
Gang Chen
Douglas Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3353212T3 publication Critical patent/DK3353212T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16781236.1T 2015-09-23 2016-09-23 Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf DK3353212T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222605P 2015-09-23 2015-09-23
PCT/US2016/053525 WO2017053856A1 (en) 2015-09-23 2016-09-23 Optimized anti-cd3 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK3353212T3 true DK3353212T3 (da) 2021-12-20

Family

ID=57130447

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16781236.1T DK3353212T3 (da) 2015-09-23 2016-09-23 Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf

Country Status (28)

Country Link
US (2) US20180355038A1 (da)
EP (1) EP3353212B1 (da)
JP (3) JP7023231B2 (da)
KR (1) KR102777500B1 (da)
CN (1) CN108290951B (da)
AU (1) AU2016325630B2 (da)
BR (1) BR112018005445A2 (da)
CA (1) CA2999385A1 (da)
CY (1) CY1124944T1 (da)
DK (1) DK3353212T3 (da)
EA (1) EA201890785A1 (da)
ES (1) ES2901133T3 (da)
HR (1) HRP20220133T8 (da)
HU (1) HUE057683T2 (da)
IL (1) IL258036B (da)
LT (1) LT3353212T (da)
MA (1) MA42935B1 (da)
MD (1) MD3353212T2 (da)
MX (1) MX2018003403A (da)
MY (1) MY195059A (da)
PL (1) PL3353212T3 (da)
PT (1) PT3353212T (da)
RS (1) RS62859B1 (da)
SI (1) SI3353212T1 (da)
SM (1) SMT202200050T1 (da)
TW (2) TWI783914B (da)
WO (1) WO2017053856A1 (da)
ZA (1) ZA201801673B (da)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
PT3221359T (pt) 2014-11-17 2020-06-23 Regeneron Pharma Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20
JP6773679B2 (ja) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
CN107646038B (zh) * 2015-05-28 2021-08-20 基因泰克公司 用于检测抗cd3同二聚体的基于细胞的测定
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
DK3353212T3 (da) * 2015-09-23 2021-12-20 Regeneron Pharma Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
IL314779A (en) 2016-04-20 2024-10-01 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
US11530277B2 (en) 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP4273172A3 (en) * 2016-09-23 2024-02-28 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
NZ795790A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-BCMA heavy chain-only antibodies
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
TWI789399B (zh) * 2017-06-22 2023-01-11 財團法人生物技術開發中心 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
PL3665198T3 (pl) * 2017-08-09 2025-06-09 Merus N.V. Przeciwciała wiążące egfr i cmet
EA201990784A1 (ru) * 2017-09-14 2019-09-30 Ридженерон Фармасьютикалз, Инк. Анти-muc16 (mucin16) антитела
CA3076632A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
AU2018395273A1 (en) * 2017-12-27 2020-08-13 Teneobio, Inc. CD3-delta/epsilon heterodimer specific antibodies
US11548947B2 (en) 2018-06-21 2023-01-10 Regeneron Pharmaceuticals, Inc. Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
UY38289A (es) 2018-07-02 2020-01-31 Amgen Inc Proteína de unión al antígeno anti-steap1
PT3823665T (pt) 2018-07-19 2024-02-26 Regeneron Pharma Recetores antigénicos quiméricos que possuem uma especificidade para o bcma e utilizações dos mesmos
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
EA202190601A1 (ru) 2018-08-23 2021-07-14 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА АНТИ-Fc ЭПСИЛОН-R1 АЛЬФА (FCER1A), БИСПЕЦИФИЧЕСКИЕ АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕ FCΕR1Α И CD3, И ИХ ПРИМЕНЕНИЕ
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
JP2022512684A (ja) 2018-10-11 2022-02-07 インヒブルクス インコーポレイテッド Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
TWI863932B (zh) 2018-10-11 2024-12-01 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
CA3121842A1 (en) * 2018-12-04 2020-03-19 Novartis Ag Binding molecules against cd3 and uses thereof
TWI821474B (zh) * 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
EP3897715A1 (en) 2018-12-19 2021-10-27 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
CN113166268B (zh) 2018-12-19 2024-07-30 瑞泽恩制药公司 双特异性抗muc16 x抗cd28抗体以及其用途
CN113661177B (zh) 2019-03-22 2024-04-16 里珍纳龙药品有限公司 EGFR x CD28多特异性抗体
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
KR20220024594A (ko) * 2019-06-21 2022-03-03 리제너론 파마슈티칼스 인코포레이티드 Psma 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용
US12091460B2 (en) * 2019-06-21 2024-09-17 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
AU2020308868A1 (en) * 2019-06-26 2022-01-20 Amunix Pharmaceuticals, Inc. CD3 antigen binding fragments and compositions comprising same
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
MX2022001942A (es) 2019-08-15 2022-07-27 Regeneron Pharma Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
CN116057070A (zh) * 2019-10-23 2023-05-02 礼进生物医药科技（上海）有限公司 抗cd40结合分子和包括其的双特异性抗体
JP7693672B2 (ja) 2019-12-06 2025-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
SI4284512T1 (sl) 2021-01-28 2025-06-30 Regeneron Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
WO2022192895A1 (en) * 2021-03-10 2022-09-15 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20250019439A1 (en) * 2021-11-24 2025-01-16 Adimab, Llc Anti-idiotype antibodies
CN119213023A (zh) 2022-03-29 2024-12-27 恩格姆生物制药公司 Ilt3和cd3结合剂以及其使用方法
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN114685675B (zh) * 2022-04-27 2023-02-03 深圳市汉科生物工程有限公司 双特异性抗体及其在治疗癌症中的用途
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
EP4601748A1 (en) 2022-10-10 2025-08-20 Regeneron Pharmaceuticals, Inc. Methods for reducing alloantibody levels in subjects in need of solid organ transplantation
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
WO2024191983A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific anti-cd22 x anti-cd28 molecules
WO2025014913A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1xcd28 antibodies and methods of use thereof
TW202519547A (zh) 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1x4-1BB抗體及其使用方法
WO2025080533A1 (en) * 2023-10-09 2025-04-17 Janux Therapeutics, Inc. Antibodies targeting steap-1 and cd3 and uses thereof
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
US20250297006A1 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
US20250313641A1 (en) 2024-04-09 2025-10-09 Amgen Inc. Agonistic anti-il-2rbg heavy-chain antibodies
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1487487A2 (en) * 2001-09-28 2004-12-22 Elusys Therapeutics, Inc. Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2356154A4 (en) * 2008-11-06 2012-12-19 Alexion Pharma Inc DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011056997A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
KR101681818B1 (ko) * 2011-08-23 2016-12-01 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
AU2013271737A1 (en) * 2012-06-05 2015-01-22 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
DE102012214441B4 (de) * 2012-08-14 2020-08-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Messverfahren
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
PL2900694T3 (pl) * 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
EP2904016B1 (en) * 2012-10-08 2018-11-14 Roche Glycart AG Fc-free antibodies comprising two fab-fragments and methods of use
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA2925677A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
DK3353212T3 (da) * 2015-09-23 2021-12-20 Regeneron Pharma Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
EP4273172A3 (en) * 2016-09-23 2024-02-28 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates
MX2019003325A (es) * 2016-09-23 2019-08-05 Regeneron Pharma Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos.
MX2022001942A (es) * 2019-08-15 2022-07-27 Regeneron Pharma Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.

Also Published As

Publication number Publication date
SMT202200050T1 (it) 2022-03-21
RS62859B1 (sr) 2022-02-28
TW201726713A (zh) 2017-08-01
JP2018537516A (ja) 2018-12-20
IL258036A (en) 2018-05-31
PT3353212T (pt) 2022-01-05
KR102777500B1 (ko) 2025-03-11
MA42935A (fr) 2018-08-01
KR20180050412A (ko) 2018-05-14
JP7023231B2 (ja) 2022-02-21
EA201890785A1 (ru) 2018-10-31
HUE057683T2 (hu) 2022-05-28
HRP20220133T8 (hr) 2022-05-13
MA42935B1 (fr) 2022-02-28
TW202241514A (zh) 2022-11-01
CA2999385A1 (en) 2017-03-30
TWI783914B (zh) 2022-11-21
HRP20220133T1 (hr) 2022-04-15
AU2016325630B2 (en) 2022-11-17
HK1258304A1 (en) 2019-11-08
CY1124944T1 (el) 2023-01-05
MX2018003403A (es) 2018-05-28
ES2901133T3 (es) 2022-03-21
JP2023154021A (ja) 2023-10-18
JP2022064886A (ja) 2022-04-26
EP3353212A1 (en) 2018-08-01
TWI784917B (zh) 2022-11-21
CN108290951B (zh) 2022-04-01
US20210253701A1 (en) 2021-08-19
ZA201801673B (en) 2022-12-21
BR112018005445A2 (pt) 2018-10-09
SI3353212T1 (sl) 2022-01-31
AU2016325630A1 (en) 2018-04-26
MD3353212T2 (ro) 2022-03-31
EP3353212B1 (en) 2021-11-03
US20180355038A1 (en) 2018-12-13
WO2017053856A1 (en) 2017-03-30
PL3353212T3 (pl) 2022-03-28
LT3353212T (lt) 2021-12-27
JP7695877B2 (ja) 2025-06-19
IL258036B (en) 2022-09-01
CN108290951A (zh) 2018-07-17
MY195059A (en) 2023-01-05

Similar Documents

Publication Publication Date Title
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
IL253166B (en) Bispecific antibodies against cd3 and cd20
DK3541841T3 (da) Anti-PD-1-antistoffer og sammensætninger
DK3356404T3 (da) Anti-pd1-antistoffer og fremgangsmåder til anvendelse
DK3191135T3 (da) Anti-HER2-antistoffer og immunokonjugater
DK3356411T3 (da) Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3229838T3 (da) Anti-C10orf54-antistoffer og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3126388T3 (da) Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
DK3309174T3 (da) ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
DK3227336T3 (da) Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
DK3310812T3 (da) Anti-HER2-antistoffer og fremgangsmåder til anvendelse
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3463435T3 (da) Alpha-synuklein-antistoffer og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3561057T3 (da) Anti-cd3-antistof og molekyle indeholdende nævnte antistof